Several clinical trials and studies highlighted the bidirectional crosstalk between HER2 and ER when both receptors are expressed in BC cells, where the main role of ER signalling in those tumours is to act as a mechanism of resistance to HER2 inhibition [7, 8, 11, 28, 29, 64–66]. The gene discussed is ERBB2; the disease is breast cancer.